Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Cash from Operations (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Cash from Operations for 16 consecutive years, with 13481000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 109.22% year-over-year to 13481000.0, compared with a TTM value of 339305000.0 through Dec 2025, up 169.07%, and an annual FY2025 reading of 179552000.0, up 138.79% over the prior year.
  • Cash from Operations was 13481000.0 for Q4 2025 at Arrowhead Pharmaceuticals, down from 20491000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 460053000.0 in Q1 2025 and bottomed at 154720000.0 in Q2 2025.
  • Average Cash from Operations over 5 years is 17480250.0, with a median of 46489500.0 recorded in 2021.
  • The sharpest move saw Cash from Operations surged 1056.58% in 2021, then tumbled 455.51% in 2024.
  • Year by year, Cash from Operations stood at 61308000.0 in 2021, then dropped by 23.17% to 75516000.0 in 2022, then crashed by 56.05% to 117840000.0 in 2023, then fell by 24.13% to 146272000.0 in 2024, then soared by 109.22% to 13481000.0 in 2025.
  • Business Quant data shows Cash from Operations for ARWR at 13481000.0 in Q4 2025, 20491000.0 in Q3 2025, and 154720000.0 in Q2 2025.